Search
Diclofenamide
go.drugbank.com/drugs/DB01144ApprovedA carbonic anhydrase inhibitor that is used in the treatment of glaucoma.
Vorapaxar
go.drugbank.com/drugs/DB09030ApprovedBy inhibiting PAR-1, a thrombin receptor expressed on platelets, vorapaxar prevents thrombin-related platelet aggregation. … Vorapaxar is a tricyclic himbacine-derived selective inhibitor of protease activated receptor (PAR-1) indicated for reducing the incidence of thrombotic cardiovascular events in patients with a history
Synonyms: Ethyl N-[(3R,3aS,4S,4aR,7R,8aR,9aR)-4-[(E)-2-[5-(3-fluorophenyl)-2-pyridyl]vinyl]-3-methyl-1-oxo-3a,4,4a,5,6,7,8,8a,9,9a-decahydro-3H-benzo[f]isobenzofuran-7-yl]carbamate, Carbamic acid, N-[(1R,3aR,4aR,6R,8aR,9S,9aS)-9-[(E)-2-[5-(3-fluorophenyl)-2-pyridinyl]ethenyl]dodecahydro-1-methyl-3-oxonaphtho[2,3-c]furan-6-yl]-, ethyl esterIcosapent
go.drugbank.com/drugs/DB00159ApprovedInvestigationalNutraceuticalA diet rich in eicosapentaenoic acid lowers serum lipid concentration, reduces incidence of cardiovascular disorders, prevents platelet aggregation, and inhibits arachidonic acid conversion into the thromboxane … Important polyunsaturated fatty acid found in fish oils. It serves as the precursor for the prostaglandin-3 and thromboxane-3 families.
Mixtures: Live-well™ Toco-E Capsule, Virt-PN PlusLM-609
go.drugbank.com/drugs/DB05787ExperimentalLM-609 (Vitaxin) is an artificial antibody that targets a protein on the surface of newly forming blood vessels, as well as on certain tumors. … In addition to cancer, the protein has been implicated in bone destruction in rheumatoid arthritis and the inflammatory process in psoriasis.
Ardeparin
go.drugbank.com/drugs/DB00407ApprovedWithdrawnIts molecular weight ranges from 2000 to 15,000 with an average molecular weight of 5500 to 6500. Normiflo was withdrawn from the US market in March 2000. … Ardeparin, marketed under the US trade name Normiflo, is a low molecular weight heparin (LMWH) anticoagulant used for the prevention of postoperative venous thrombosis.
Darvadstrocel
go.drugbank.com/drugs/DB16581ApprovedInvestigationalWithdrawnIt is indicated for the treatment of complex perianal fistulas in adult patients with non-active or mildly active luminal Crohn’s disease when fistulas have shown an inadequate response to at least one … [L39759] It is the first mesenchymal stem cell therapy approved in Europe for this therapeutic indication.
Indacaterol
go.drugbank.com/drugs/DB05039ApprovedInvestigationalIt was approved by the European Medicines Agency (EMA) on 30 November 2009 and by the FDA on 1 July 2011. It is marketed in Europe as Onbrez and in America as Arcapta Neohaler. … Indacaterol is also a chiral molecule but only the pure R-enantiomer is dispensed.
Products: ONBREZ BREEZHALER 150UG HAOmaveloxolone
go.drugbank.com/drugs/DB12513ApprovedInvestigationalTherefore, the use of Nrf2 activators such as omaveloxolone represents a therapeutic advantage in this group of patients. … In patients with Friedreich's ataxia, a genetic disease involving mitochondrial dysfunction, the Nrf2 pathway is impaired, and Nrf2 activity is lower.
Synonyms: Propanamide, N-(2-cyano-3,12-dioxo-28-noroleana-1,9(11)-dien-17-yl)-2,2-difluoro-Ibrexafungerp
go.drugbank.com/drugs/DB12471Approved[A235414,L34349] Ibrexafungerp was granted FDA approval on 1 June 2021.[L34349] … [A235384,A235389] Similar to echinocandins, ibrexafungerp targets the fungal β-1,3-glucan synthase, which is not present in humans, limiting the chance of renal or hepatic toxicity.
Eslicarbazepine acetate
go.drugbank.com/drugs/DB09119ApprovedInvestigationalEslicarbazepine acetate is a prodrug that is rapidly converted to eslicarbazepine, the primary active metabolite in the body. … Eslicarbazepine acetate (ESL) is an anticonvulsant medication approved for use in Europe, the United States and Canada as an adjunctive therapy for partial-onset seizures that are not adequately controlled